Streetwise Articles



Brett Earl

Medical Use of Nitric Oxide Expands as Costs Come Down
Source: Streetwise Reports††(9/19/18)
Dr. Brett Earl, a practicing physician and a vice president and director of Nu-Med Plus, discusses the many uses of nitric oxide and Nu-Med Plus' unique, low-cost delivery system. More >


Coverage Initiated on 'Emerging Antibiotics Growth Story with Multiple Levers for Upside'
Source: Streetwise Reports††(9/19/18)
An H.C. Wainwright & Co. report outlined the investment thesis for this U.S.-based biopharmaceutical firm. More >


Cancer Vaccine Developer Expands Its Collaboration with Merck
Source: Streetwise Reports††(9/19/18)
A Mackie Research Capital report tells how this biotech will benefit from its new and existing programs with this specific partner. More >


U.S. Biotech Partner Obtains Marketing Authorization for ADHD Treatment in Taiwan
Source: Streetwise Reports††(9/18/18)
Permission has been obtained to distribute time-release capsules. More >


Daniel Carlson

Why Tiny ITUS's CAR-T Therapy Could Be a Big Deal in Cancer Treatment
Source: Daniel Carlson for Streetwise Reports††(9/14/18)
With CAR-T being the hottest space in cancer therapy, Daniel Carlson of Tailwinds Research profiles an innovative company that has been collaborating with a major cancer center. More >


Canadian Biopharma to Outlicense Pain Drug to South Korean Firm
Source: Streetwise Reports††(9/12/18)
An Echelon Wealth Partners report discussed the deal terms.
More >


Biopharma's Positive FDA Meeting Outlines Path Forward for Trial
Source: Streetwise Reports††(9/11/18)
A ROTH Capital Partners note explained the outcome of the tÍte-a-tÍte and its implications.


More >


Coverage Initiated on Firm with Paradigm-Shifting Colonoscopy Device
Source: Streetwise Reports††(9/5/18)
A Ladenburg Thalmann report covered the asset, product market and financial projections of this Florida-based company. More >


Final Approval of Biopharma's Lead Candidate Both Likely and Imminent
Source: Streetwise Reports††(9/5/18)
A ROTH Capital Partners report provided the takeaways from a recent meeting with the management team for this company, which is targeting an orphan indication. More >


Drug Company Receives $5 Million Milestone Payment
Source: Streetwise Reports††(8/31/18)
Company entitled to receive quarterly earn-out payments from patent agreement. More >


Neurosciences Company Reports Potential for Improved Safety Profile for Alzheimer's Treatment
Source: Streetwise Reports††(8/29/18)
The substance shows potential for an improved safety profile in direct comparison to other Amyloid Beta-Directed Antibodies in clinical development. More >


Oncology-Focused Biotech Receives Orphan Status for AML Drug
Source: Streetwise Reports††(8/29/18)
An H.C. Wainwright & Co. report provided an update on two of this company's four product candidates. More >


Investor Opportunity Arises from Biopharma's Share Price Weakness on Competitor News
Source: Streetwise Reports††(8/29/18)
An analyst discussed the implications to this firm of a competitive product's advancement.
More >


Ronald Day

As Nitric Oxide Comes Off Patent, Lower-Cost Options for Life Saving Drug Becoming Possible
Source: Streetwise Reports††(8/22/18)
Dr. Ronald Day, a pediatric cardiologist at the University of Utah, has been using nitric oxide to treat children with pulmonary hypertension. Now, with a court ruling invalidating much of a drug patent for nitric oxide, lower-cost options might become available. More >


Coverage Initiated on Developer of Brachytherapy Products for Cancer Treatment
Source: Streetwise Reports††(8/22/18)
H.C. Wainwright & Co. analyst Jason Kolbert provided the rationale for investment in this company. More >


Biosciences Company Announces Research Collaboration for Testing Cannabis Ingredients
Source: Streetwise Reports††(8/21/18)
The development of analytic methods is a key milestone in the development of water-soluble cannabis technology. More >


Medical Device Firm Anticipates Benefit from Patent Ruling
Source: Streetwise Reports††(8/15/18)
This company, which develops delivery products for inhaled nitric oxide, a gas used to treat newborns with low oxygen levels and patients with COPD, sees opportunity in a newly invalidated patent. More >


Medical Device Firm's Clinical Programs Progress in Q2/18
Source: Streetwise Reports††(8/15/18)
A Ladenburg Thalmann report reviewed the recent financial results for a California-based company that has developed treatments for vaginal laxity and female stress urinary incontinence. More >


Biotech Marks Progress on Programs for Cancer, Infectious Diseases
Source: Streetwise Reports††(8/15/18)
This firm, focused on immuno-oncology and infectious diseases including Ebola and Zika, is moving forward on a variety of fronts, according to a Maxim Group analyst. More >


Biopharma Signs Multimillion-Dollar Deal for Key Products in China
Source: Streetwise Reports††(8/8/18)
An H.C. Wainwright & Co. report reviewed the arrangement. More >


U.S. Medical Device Firm Pursues ISO 13485 Certification
Source: Streetwise Reports††(8/1/18)
With this move, this company aims for fast-tracked regulatory approval for its nitric oxide delivery system. More >


Cash Stream from Licensing Deal to Help Biopharma Advance Lead Drug
Source: Streetwise Reports††(8/1/18)
A Laidlaw & Co. report discussed this firm's revenue and near-term, clinical catalysts. More >


Biotech Releases White Paper on Alzheimer's Disease Candidate
Source: Streetwise Reports††(8/1/18)
A company focused on treatment of neurodegenerative diseases has issued a white paper discussing its lead candidate. More >


Interim Readout for Pharma Trial 'Delivers Home Run'
Source: Streetwise Reports††(7/31/18)
An H.C. Wainwright & Co. report discussed the implications of data indicating "overwhelming evidence of efficacy" for this company's nonantibiotic anti-infective for treatment of catheter-related bloodstream infections. More >


Health Technology Stock 'Set to Break Higher'
Source: Clive Maund for Streetwise Reports††(7/24/18)
Technical analyst Clive Maund charts a health technology stock whose platform allows hospitals and healthcare organizations to buy, sell and trade surplus medical equipment and supplies. More >


Showing Results: 1 to 25 of 930 Next

Notable Quotes

"PMN anticipates launching its first in-human trial in 2019 of PMN310."
– John Vandermosten, Zacks Small-Cap Research

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts